Top Biotech Stocks To Keep An Eye On - October 16th

Key Points

• MarketBeat highlights Recursion Pharmaceuticals, Danaher, and Vertex Pharmaceuticals as key biotech stocks to watch due to their high trading volume and innovation in drug development.
• Recursion Pharmaceuticals is currently conducting multiple clinical trials for treatments targeting various serious conditions, including cerebral cavernous malformation and neurofibromatosis type 2.
• Vertex Pharmaceuticals focuses on therapies for cystic fibrosis, marketing multiple medications approved for patients as young as one year old with specific genetic mutations.

Recursion Pharmaceuticals, Danaher, and Vertex Pharmaceuticals are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies that research, develop, and commercialize biological and medical products such as drugs, diagnostics, and gene therapies. For investors they are often high‑risk, high‑reward assets whose valuations are driven by scientific progress, clinical trial results, intellectual property and regulatory approvals, which can create significant volatility. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

Recursion Pharmaceuticals (RXRX)

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

Read Our Latest Research Report on RXRX

Danaher (DHR)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Read Our Latest Research Report on DHR

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Read Our Latest Research Report on VRTX